Your browser doesn't support javascript.
loading
Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation.
Li, Haiwei; Sun, Weiping; Wang, Zefeng; Wang, Ziyu; Du, Xiao; Chen, Junjun; Gao, Jianwei; Liu, Xuxia; Wang, Xipeng; Wang, Yueli; Wu, Yongquan; Zhang, Xiaoping.
Affiliation
  • Li H; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Sun W; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Wang Z; Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China.
  • Wang Z; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing, China.
  • Du X; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Chen J; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Gao J; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Liu X; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Wang X; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Wang Y; Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China.
  • Wu Y; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Zhang X; Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China.
Front Cardiovasc Med ; 9: 961914, 2022.
Article in En | MEDLINE | ID: mdl-36312240
ABSTRACT

Background:

Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) remains unknown. Materials and

methods:

Serum TIMP-1 levels of patients with AF before they underwent initial RFCA were measured using ELISA. Univariate and multivariate-adjusted Cox models were constructed to determine the relationship between TIMP-1 levels and AF recurrence. Multivariate logistic regression analyses were performed to determine predictors of AF recurrence.

Results:

Of the 194 enrolled patients, 61 (31.4%) had AF recurrence within the median 30.0 months (interquartile range 16.5-33.7 months) of follow-up. These patients had significantly higher baseline TIMP-1 levels than those without AF recurrence (129.8 ± 65.7 vs. 112.0 ± 51.0 ng/ml, P = 0.041). The same was true of high-sensitivity C-reactive protein (3.9 ± 6.0 vs. 1.9 ± 2.8 ng/ml, P = 0.001). When a TIMP-1 cutoff of 124.15 ng/ml was set, patients with TIMP-1 ≥ 124.15 ng/ml had a higher risk of recurrent AF than those with TIMP-1 < 124.15 ng/ml (HR, 1.961, 95% CI, 1.182-2. 253, P = 0.009). Multivariate Cox regression analysis revealed that high TIMP-1 was an independent risk factor for AF recurrence. Univariate Cox regression analysis found that substrate modification surgery does not affect AF recurrence (P = 0.553). Subgroup analysis revealed that female sex, age < 65 years, hypertension (HTN), body mass index (BMI) ≥ 24 kg/m2, CHA2DS2-VASc score < 2, HAS-BLED score < 3, and EHRA score = 3 combined with high TIMP-1 level would perform well at predicting AF recurrence after RFCA.

Conclusion:

Elevated preoperative TIMP-1 levels are related to a higher risk of AF recurrence and can independently predict AF recurrence following RFCA.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2022 Document type: Article Affiliation country: China Country of publication: CH / SUIZA / SUÍÇA / SWITZERLAND

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2022 Document type: Article Affiliation country: China Country of publication: CH / SUIZA / SUÍÇA / SWITZERLAND